| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Appraisal in development. |
| Process | STA Standard |
| ID number | 5084 |
Provisional Schedule
| Expected publication | 01 May 2024 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TAteam1@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews Ltd |
Stakeholders
| Companies sponsors | Merck Sharp & Dohme |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Lymphoma Action |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary (BNF) | |
| Department of Health - Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 March 2024 - 11 April 2024 | Final draft guidance |
| 13 February 2024 | Committee meeting: 1 |
| 01 February 2024 | In progress |
| 11 July 2023 | Invitation to participate |
For further information on our processes and methods, please see our CHTE processes and methods manual